Design and synthesis of novel triazole-metronidazole boswellic acid hybrids for ovarian cancer targeting

Key Points

• Novel triazole-metronidazole-boswellic acid hybrids show promising activity against ovarian cancer.
• Combination of triazole and metronidazole enhances antitumor efficacy in preclinical models.
• Synthesis involves designing compounds to target ovarian cancer, aiming to improve treatment outcomes.
• Highlights the need for further research into hybrid compounds for effective cancer therapies.